1. Wiviott, S.D. and R.P. Giugliano, 2013. Non-ST-Elevation Acute Coronary Syndromes. In: Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease, Antman, E.M. and M.S. Sabatine (Eds.). 4th Edn., WB Saunders, Philadelphia, pp: 153-177.
2. Tam, L.M., G.C. Fonarow, D.L. Bhatt, M.V. Grau-Sepulveda and A.F. Hernandez et al., 2013. Achievement of guideline-concordant care and in-hospital outcomes in patients with coronary artery disease in teaching and nonteaching hospitals: Results from the get with the guidelines-coronary artery disease program. Circ. Cardiovasc. Qual. Outcomes, 6: 58-65.
   CrossRef  |  PubMed  |  
3. Lopes, R.D., J.A. White, P. Tricoci, H.D. White and P.W. Armstrong et al., 2013. Age, treatment and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS Trial. Int. J. Cardiol., 167: 2580-2587.
   CrossRef  |  PubMed  |  
4. Hochholzer, W. and R.P. Giugliano, 2013. Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD? Curr. Atheroscler. Rep., 15: 1-10.
5. Giugliano, R.P. and E. Braunwald, 2013. Non-ST Elevation Acute Coronary Syndromes. In: Braunwald's Heart Disease, Libby, P., R.O. Bonow, D.L. Mann and D.P. Zipes (Eds.). 10th Edn., Saunders Elsevier, Philadelphia.
6. Dogliotti, A., E. Paolasso and R.P. Giugliano, 2013. Novel oral anticoagulants in atrial fibrillation: A meta-analysis of large, randomized, controlled trials vs warfarin. Clin. Cardiol., 36: 61-67.
   CrossRef  |  Direct Link  |  
7. Chan, M.Y., J.L. Sun, L.K. Newby, Y. Lokhnygina and H.D. White et al., 2013. Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. Int. J. Cardiol., 167: 548-554.
   CrossRef  |  PubMed  |  
8. Wessler, J.D., F. Saldana and R.P. Giugliano, 2012. Bridging therapy after recent stent implantation: Case report and review of data. Cardiovasc. Revasc. Med., 13: 30-38.
   CrossRef  |  Direct Link  |  
9. Thomas, D. and R.P. Giugliano, 2012. Management of non-ST-segment elevation acute coronary syndrome: Comparison of the updated guidelines from North America and Europe. Crit. Pathways Cardiol., 11: 62-73.
10. Salazar, D.E., J. Mendell, H. Kastrissios, M. Green and T.J. Carrothers et al., 2012. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost., 107: 1-12.
    CrossRef  |  PubMed  |  
11. Ruff, C.T., R.P. Giugliano, E.M. Antman, S.A. Murphy and C. Lotan et al., 2012. Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. Int. J. Cardiol., 155: 424-429.
    CrossRef  |  Direct Link  |  
12. Roe, M.T., J.A. White, P. Kaul, P. Tricoci and Y. Lokhnygina et al., 2012. Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: Insights from the EARLY ACS Trial. Circ. Cardiovasc. Qual. Outcomes, 5: 205-213.
    CrossRef  |  PubMed  |  
13. Pride, Y.B., S. Mohanavelu, C. Zorkun, V. Kunadian and R.P. Giugliano et al., 2012. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: An EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. JACC Cardiovasc. Interv., 5: 927-935.
    CrossRef  |  PubMed  |  
14. Piccini, J.P., J.A. White, R.H. Mehta, Y. Lokhnygina and S.M. Al-Khatib et al., 2012. Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. Circulation, 126: 41-49.
    CrossRef  |  PubMed  |  
15. Nicholau, J.C., C.V. Serrano, R.R. Giraldez, L.M. Baracioli and H.G. Moreira et al., 2012. In patients with acute myocardial infarction, the impact of hyperglycemia as a risk factor for mortality is not homogeneous across age-groups. Diabetes Care, 35: 150-152.
    CrossRef  |  Direct Link  |  
16. Mogabgab, O., R.P. Giugliano, M.S. Sabatine, C.P. Cannon and S. Mohanavelu et al., 2012. Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction. Chronobiol. Int., 29: 1390-1396.
    CrossRef  |  PubMed  |  
17. Leonardi, S., L. Thomas, M.L. Neely, P. Tricoci and R.D. Lopes et al., 2012. Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction. J. Am. Coll. Cardiol., 60: 2296-2304.
    CrossRef  |  PubMed  |  
18. Kohli, P., N.R. Desai, R.P. Giugliano, J.B. Kim and R. Somaratne et al., 2012. Design and rationale of the LAPLACE-TIMI 57 trial: A phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. Clin. Cardiol., 35: 385-391.
    CrossRef  |  PubMed  |  
19. Grip. L.T. and R.P. Giugliano, 2012. Importance of dose selection in novel oral anticoagulants for atrial fibrillation. Arch. Cardiol. Mex., 82: 308-311.
20. Giugliano, R.P., N.R. Desai, P. Kohli, W.J. Rogers and R. Somaratne et al., 2012. Efficacy, safety and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet, 380: 2007-2017.
    CrossRef  |  PubMed  |  
21. Giugliano, R.P., 2012. Relationships among race, bleeding and mortality in coronary reperfusion. Circulation, 125: 1715-1717.
    CrossRef  |  PubMed  |  
22. Giugliano, R.P. and E. Braunwald, 2012. The year in non-ST-segment elevation acute coronary syndrome. J. Am. Coll. Cardiol., 60: 2127-2139.
23. Desai, N.R. and R.P. Giugliano, 2012. Can we predict outcomes in atrial fibrillation? Clin. Cardiol., 35: 10-14.
    CrossRef  |  PubMed  |  
24. Del Rio-Santiago, V., R. Santiago-Trinidad, N. Espinell-Gonzalez, J. Valentin-Nieves, R.P. Giugliano, L. Rodriguez-Ospina and S. Vicenty-Rivera, 2012. Prevalence of anemia in a Hispanic population with decompensated congestive heart failure. Bol. Assoc. Med., 103: 28-33.
    PubMed  |  
25. Wang, T.Y., J.A. White, P. Tricocci, R.P. Giugliano and U. Zeymer et al., 2011. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Circulation, 123: 722-730.
    CrossRef  |  PubMed  |  
26. Tricocci, P., L.K. Newby, V. Hasselblad, D.F. Kong and R.P. Giugliano et al., 2011. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: A systematic overview of randomized clinical trials. Circ. Cardiovasc. Qual. Outcomes, 4: 448-458.
    PubMed  |  
27. Silletta, M.G., M. Scarano, R. Pioggiarella, A.P. D'Iingianna, R. Giugliano, M. Ruo and R. Marchioli, 2011. Lyfestiles, health and cardiovascular risk: The results of the study. Rischio. Prevenzione, 30: 198-207.
28. Reddy, P., J.K. Atay, L.G. Selbovitz, J.M. Connors and G. Piazza et al., 2011. Dabigatran: A review of clinical and pharmacoeconomic evidence. Crit. Pathways Cardiol., 10: 117-127.
29. Pollack, C.V., G.X. Brogan, M. Cohen, D. Diercks and C. Grines et al., 2011. ED to catheterization laboratory: A roundtable integrating trials with practice. Am. J. Emerg. Med., 29: 1203-1216.
    CrossRef  |  PubMed  |  
30. Partida, R.A. and R.P. Giugliano, 2011. Edoxaban: Pharmacological principles, preclinical and early phase clinical testing. Future Med., 7: 459-470.
    CrossRef  |  PubMed  |  
31. Melloni, C., S.K. James, J.A. White, R.P. Giugliano and R.A. Harrington et al., 2011. Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. Am. Heart J., 162: 884-892.
    CrossRef  |  Direct Link  |  
32. Kim, S.J., R.P. Giugliano and I.K. Jang, 2011. Adjunctive pharmacologic therapy in percutaneous coronary intervention: Part II anticoagulant therapy. Coron. Artery Dis., 22: 113-121.
33. Hochholzer, W., S.D. Wiviott, E.M. Antman, C.F. Contant and J. Guo et al., 2011. Predictors of bleeding and time dependence of association of bleeding with mortality: Insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation, 123: 2681-2689.
    CrossRef  |  PubMed  |  
34. Hochholzer, W., D.D. Berg and R.P. Giugliano, 2011. The facts behind niacin. Ther. Adv. Cardiovasc. Dis., 5: 227-240.
    CrossRef  |  PubMed  |  
35. Giugliano, R.P., 2011. Niacin at 56 years of age-time for an early retirement? New Engl. J. Med., 365: 2318-2320.
36. Giugliano, R.P. and E. Braunwald, 2011. The year in non-ST-segment elevation acute coronary syndrome. J. Am. Coll. Cardiol., 58: 2342-2354.
37. Ehle, M., C. Patel and R.P. Giugliano, 2011. Digoxin: Clinical highlights: A review of digoxin and its use in contemporary medicine. Crit. Pathw. Cardiol., 10: 93-98.
    CrossRef  |  PubMed  |  
38. Baron, S.J. and R.P. Giugliano, 2011. Effectiveness and safety of percutaneous coronary intervention after fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am. J. Cardiol., 107: 1001-1009.
    CrossRef  |  PubMed  |  
39. Thomas, D. and R.P. Giugliano, 2010. Perspectives on the 2009 focused updates on the management of ST-segment elevation myocardial infarction and percutaneous intervention. Crit. Pathw. Cardiol., 9: 126-133.
    CrossRef  |  PubMed  |  
40. Thomas, D. and R.P. Giugliano, 2010. Day 1 care in patients with non-ST-segment elevation myocardial infarction. Cardiovasc. Revasc. Med., 11: 41-51.
    CrossRef  |  PubMed  |  
41. Tam, L.M. and R.P. Giugliano, 2010. Glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes. Arch. Med. Sci., 6: S35-S47.
42. Ruff, C.T., R.P. Giugliano, E.M. Antman, S.E. Crugnale and T. Bocanegra et al., 2010. Evaluation of the novel factor Xa inhibitor edoxaban compared with Warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am. Heart J., 160: 635-641.
43. Rich, J.D., C.P. Cannon, S.A. Murphy, J. Qin, R.P. Giugliano and E. Braunwald, 2010. Prior aspirin use and outcomes in acute coronary syndromes. J. Am. Coll. Cardiol., 56: 1376-1385.
44. Kaul, S., A.F. Bolger, D. Herrington, R.P. Giugliano and R.H. Eckel, 2010. Thiazolidinedione drugs and cardiovascular risks: A science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation, 121: 1868-1877.
    CrossRef  |  PubMed  |  
45. Hochholzer, W., D.A. Morrow and R.P. Giugliano, 2010. Novel biomarkers in cardiovascular disease: Update 2010. Am. Heart J., 160: 583-594.
    CrossRef  |  
46. Hochholzer, W. and R.P. Giugliano, 2010. Lipid lowering goals: Back to nature? Ther. Adv. Cardiovasc. Dis., 4: 185-1891.
47. Harkness, J.R., M.S. Sabatine, E. Braunwald, D.A. Morrow and S. Sloan et al., 2010. Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. Am. Heart J., 159: 55-62.
    CrossRef  |  Direct Link  |  
48. Giugliano, R.P., R.R. Giraldez, D.A. Morrow, E.M. Antman and C.M. Gibson et al., 2010. Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. Eur. Heart J., 31: 2103-2110.
    CrossRef  |  PubMed  |  
49. Giugliano, R.P. and E. Braunwald, 2010. The year in non-ST-segment elevation acute coronary syndrome. J. Am. Coll. Cardiol., 56: 2126-2138.
50. Califf, R.M., Y. Lokhnygina, C.P. Cannon, M.E. Stepanavage and C.H. McCabe et al., 2010. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am. Heart J., 159: 705-709.
    CrossRef  |  PubMed  |  
51. Bonaca, M.P. and R.P. Giugliano, 2010. Oral antiplatelet agents: New insights in managing patients with acute coronary syndromes. Hot Topics Cardiol., 5: 7-16.
52. Bonaca, M. and R.P. Giugliano, 2010. Antithrombotics in acute coronary syndromes: Updates from the past year. Curr. Treat. Opt. Cardiovasc. Med., 12: 84-99.
53. Truong, Q.A., C.P. Cannon, N.A. Zakai, I.S. Rogers and R.P. Giugliano et al., 2009. Thrombolysis in Myocardial Infarction (TIMI) risk index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. Am. Heart J., 157: 673-679.
    CrossRef  |  Direct Link  |  
54. Thomas, D. and R.P. Giugliano, 2009. Management of ST-segment elevation myocardial infarction: comparison of the updated guidelines from North America and Europe. Am. Heart J., 69: 1433-1443.
    CrossRef  |  Direct Link  |  
55. Thomas, D. and R.P. Giugliano, 2009. ExTRACT-TIMI 25 in perspective: Key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy. J. Thromb Thrombolysis, 27: 1-10.
56. Thomas, D. and R.P. Giugliano, 2009. Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice. Crit. Pathw. Cardiol., 8: 12-19.
    CrossRef  |  PubMed  |  
57. Thao, H., J. Nasmith, T.M. Luong, M. Bernier and C. Pharand et al., 2009. Complementary prognostic values of ST segment deviation and TIMI risk score in non-ST-elevation acute coronary syndromes: Insights from the PRISM-PLUS study. Canadian J. Card., 25: e417-e421.
    Direct Link  |  
58. Ruff, C. and R.P. Giugliano, 2009. Novel oral antithrombotic and antiarrhythmic approaches for atrial fibrillation. Hot. Topics Cardiol., 4: 7-13.
59. Mousa, S.A., J.T. Willerson and R.P. Giugliano, 2009. Overview of Antiplatelet Therapy. In: New Therapeutic Agents in Thrombolysis, Freedman, J. and J. Loscalzo (Eds.). Informa Healthcare, New York.
60. Lefebvre, C.W., J.W. Hoekstra, M. Bonaca and R.P. Giugliano, 2009. Glycoprotein IIb-IIIa inhibitors in the Emergency Department for patients with non-ST-elevation acute coronary syndromes: Principles and practices. J. Emerg. Med., 36: 162-170.
61. Huynh, T., J. Nasmith, T.M. Luong, M. Bernier and C. Pharand et al., 2009. Complementary prognostic values of ST segment deviation and Thrombolysis In Myocardial Infarction (TIMI) risk score in non-ST elevation acute coronary syndromes: Insights from the platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Can. J. Cardiol., 25: e417-e421.
    Direct Link  |  
62. Hoekstra, J., M. Cohen, R. Giugliano, C.B. Granger and P.A. Gurbel et al., 2009. Expert consensus on treatment strategies in non-ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention-an evidence based review of clinical trial results and treatment guidelines from an emergency medicine perspective: Report on roundtable discussion. Am. J. Emerg. Med., 27: 72-78.
63. Giugliano, R.P., J.A. White, C. Bode, P.W. Armstrong and G. Montalescot et al., 2009. Early versus delayed, provisional eptifibatide in acute coronary syndromes. New Engl. J. Med., 360: 2176-2190.
    CrossRef  |  Direct Link  |  
64. Giugliano, R.P., 2009. Design Issues in Clinical Trials of Thrombolytic and Antithrombotic Agents. In: New Therapeutic Agents in Thrombolysis, Freedman, J. and J. Loscalzo (Eds.). Informa Healthcare, New York.
65. Giugliano, R.P. and E. Braunwald, 2009. The year in non-ST-segment elevation acute coronary syndrome. J. Am. Coll. Cardiol., 54: 1544-1555.
66. Giraldez, R.R., S.D. Wiviott, J.C. Nicolau, S. Mohanavelu, D.A. Morrow, E.M. Antman and R.P. Giugliano, 2009. Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens. Drugs, 69: 1433-1443.
67. Bonaca, M.P., S.P. Gabriel, L.J. Feldman, J.F. Canales and J.J. Ferguson et al., 2009. Antithrombotics in acute coronary syndromes. J. Am. Coll. Cardiol., 54: 969-984.
68. Thomas, D. and R.P. Giugliano, 2008. Antiplatelet therapy in early management of non-ST-segment elevation acute coronary syndrome: The 2002 and 2007 guidelines From North America and Europe. J. Cardiovasc. Pharmacol., 51: 425-433.
69. Ruff, C.T., D.A. Morrow and R.P. Giugliano, 2008. Tissue Factor Inhibitors. In: Clinical Guide to the Use of Antithrombotic Drugs in Coronary Artery Disease, ngiolilo, D.J., A. Kastrati and D.I. Simon (Eds.). London Informa UK Ltd., UK., pp: 153-159.
70. Kashani, A. and R.P. Giugliano, 2008. Management of ST-elevation myocardial infarction an update on pharmacoinvasive recanalization. Am. J. Cardiovasc. Drugs, 8: 187-197.
71. Giugliano, R.P. and E. Braunwald, 2008. The year in non-ST-segment elevation acute coronary syndrome. J. Am. Coll. Cardiol., 52: 1095-1103.
72. Giraldez, R.R., R.P. Giugliano, S. Mohanavelu, S.A. Murphy, C.H. McCabe, C.P. Cannon and E. Braunwald, 2008. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. J. Am. Coll. Cardiol., 52: 914-920.
    CrossRef  |  PubMed  |  
73. Cannon, C.P., R.P. Giugliano, M.A. Blazing, R.A. Harrington and J.L. Peterson et al., 2008. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am. Heart J., 156: 826-832.
    CrossRef  |  PubMed  |  
74. Ahmed, S., C.P. Cannon, R.P. Giugliano, S.A. Murphy and D.A. Morrow et al., 2008. The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. Int. J. Cardiol., 131: 105-112.
    CrossRef  |  Direct Link  |  
75. Yeh, R.W., S.D. Wiviott, R.P. Giugliano, D.A. Morrow and A. Shui et al., 2007. Effect of thrombocytopenia on outcomes following treatment with either Enoxaparin or unfractionated Heparin in patients presenting with acute coronary syndromes. J. Emer. Med., 100: 1734-1738.
    CrossRef  |  Direct Link  |  
76. Wiviott, S.D. and R.P. Giugliano, 2007. Non-ST-Elevation Acute Coronary Syndromes. In: Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease, Antman, E.M. (Ed.). 3rd Edn., WB Saunders, Philadelphia, pp: 221-245.
77. Scirica, B.M., D.A. Morrow, Z. Sadowski, N.J.C. Ruda and R.P. Giugliano, 2007. A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: The ExTRACT-TIMI 25 ECG Study. Eur. Heart J., 28: 2070-2076.
    PubMed  |  
78. Giugliano, R.P., S.D. Wiviott, P.H. Stone, D.I. Simon and M.J. Schweiger et al., 2007. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: The ANTHEM-TIMI-32 trial. J. Am. Coll. Cardiol., 49: 2398-2407.
    CrossRef  |  
79. Giugliano, R.P. and E. Braunwald, 2007. The year in non-ST-segment elevation acute coronary syndromes. J. Am. Coll. Cardiol., 50: 1386-1395.
80. Dorbala, S., R.P. Giugliano, G. Logsetty, D. Vangala and R. Mishra et al., 2007. Prognostic value of SPECT myocardial perfusion imaging in patients with elevated cardiac troponin I levels and atypical clinical presentation. J. Nucl. Cardiol., 14: 53-58.
    CrossRef  |  
81. Scirica, B.M., M.S. Sabatine, D.A. Morrow, C.M. Gibson and S.A. Murphy et al., 2006. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: The ECG CLARITY-TIMI 28 Study. J. Am. Coll. Cardiol., 48: 37-42.
82. Giugliano, R.P. and E. Braunwald, 2006. The year in non-ST-segment elevation acute coronary syndromes. J. Am. Coll. Cardiol., 48: 386-395.
83. Dumaine, R., C.M. Gibson, S.A. Murphy, M. Southard and H.Q. Ly et al., 2006. Association of a history of systemic hypertension with mortality, thrombotic and bleeding complications following non-ST-segment elevation acute coronary syndrome. J. Clin. Hypertens (Greenwich), 8: 315-322.
    CrossRef  |  Direct Link  |  
84. Allen, L.A., C.J. O'Donnell, C.A. Camargo, R.P. Giugliano and D.M. Lloyd-Jones, 2006. Comparison of long-term mortality across the spectrum of acute coronary syndromes. Am. Heart J., 151: 1065-1071.
    PubMed  |  
85. Ahmed, S., E.M. Antman, S.A. Murphy, R.P. Giugliano and C.P. Cannon et al., 2006. Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: Impact of age (a meta-analysis of a decade of trials). J. Thromb. Thrombolysis, 21: 119-129.
    CrossRef  |  Direct Link  |  
86. Sabatine, M.S., D.A. Morrow, R.P. Giugliano, P.B. Burton and S.A. Murphy et al., 2005. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation, 111: 2042-2049.
    PubMed  |  
87. Pinto, D.S., A.H. Skolnick, A.J. Kirtane, S.A. Murphy and H.V. Barron et al., 2005. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol., 46: 178-180.
88. Ly, H.Q., A.J. Kirtane, J. Buros, R.P. Giugliano and J.J. Popma et al., 2005. Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. Am. J. Cardiol., 95: 383-386.
    PubMed  |  
89. Kirtane, A.J., P. Martinezclark, A.M. Rahman, K.K. Ray and D. Karmpaliotis et al., 2005. Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol., 45: 321-323.
    CrossRef  |  
90. Kirtane, A.J., I. Kosmidou, D. Karmpaliotis, S.A. Murphy and R.P. Giugliano et al., 2005. Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. Am. J. Cardiol., 95: 337-342.
    CrossRef  |  Direct Link  |  
91. Kirtane, A.J., A. Weisbord, D. Karmpaliotis, S.A. Murphy and R.P. Giugliano et al., 2005. Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. Am. J. Cardiol., 95: 224-227.
92. Kashani, A., C.M. Gibson, S.A. Murphy, M.S. Sabatine, D.A. Morrow, E.M. Antman and R.P. Giugliano, 2005. Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction. Am. J. Cardiol., 95: 228-233.
    PubMed  |  
93. Ilkhanoff, L., C.J. O'Donnell, C.A. Camargo, T.D. O'Halloran, R.P. Giugliano and D.M. Lloyd-Jones, 2005. Usefulness of the TIMI Risk Index in predicting short- and long-term mortality in patients with acute coronary syndromes. Am. J. Cardiol., 96: 773-777.
    PubMed  |  
94. Giugliano, R.P., L.K. Newby, R.A. Harrington, C.M. Gibson and F. van de Werf et al., 2005. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. Am. Heart J., 149: 994-1002.
    PubMed  |  
95. Giugliano, R.P. and E. Braunwald, 2005. The year in non-ST-segment elevation acute coronary syndromes. J. Am. Coll. Cardiol., 46: 906-919.
96. Gibson, C.M., A.J. Kirtane, K. Boundy, H. Ly and D. Karmpaliotis et al., 2005. Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. J. Am. Coll. Cardiol., 45: 357-362.
    CrossRef  |  Direct Link  |  
97. Cannon, C.P., E. Braunwald, C.H. McCabe, J.T. Grayston, B. Muhlestein, R.P. Giugliano, R. Cairns and A.M. Skene, 2005. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. New Engl. J. Med., 352: 1646-1654.
    PubMed  |  
98. Wiviott, S.D., D.A. Morrow, P.D. Frederick, R.P. Giugliano and C.M. Gibson et al., 2004. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol., 44: 783-789.
99. Wiviott, S.D., C.P. Cannon, D.A. Morrow, S.A. Murphy and C.M. Gibson et al., 2004. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation, 109: 580-586.
100. Turakhia, M.P., S.A. Murphy, T.L. Pinto, E.M. Antman and R.P. Giugliano et al., 2004. Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am. J. Cardiol., 94: 1406-1410.
     PubMed  |  
101. Sabatine, M.S., D.A. Morrow, R.P. Giugliano, S.A. Murphy, L.A. Demopoulos et al., 2004. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Circulation, 109: 874-880.
     PubMed  |  
102. Roe, M.T., C.L. Green, R.P. Giugliano, C.M. Gibson and K. Baran et al., 2004. Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol., 43: 549-556.
103. Rebeiz, A.G., P. Johanson, C.L. Green, S.W. Crater and M.T. Roe et al., 2004. Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). Am. J. Cardiol., 95: 611-614.
     CrossRef  |  Direct Link  |  
104. Morrow, D.A., E.M. Antman, S.A. Murphy, S.F. Assmann and R.P. Giugliano et al., 2004. The risk score profile: A novel approach to characterising the risk of populations enrolled in clinical studies. Eur. Heart J., 25: 1139-1145.
     PubMed  |  
105. Kirtane, A.J., A. Bui, S.A. Murphy, D. Karmpaliotis and I. Kosmidou et al., 2004. Association of epicardial and tissue-level reperfusion with left ventricular end-diastolic pressures in ST-elevation myocardial infarction. J. Thromb. Thrombolysis, 17: 177-184.
     PubMed  |  
106. Kashani, A., R.P. Giugliano, E.M. Antman, D.A. Morrow, C.M. Gibson, S.A. Murphy and E. Braunwald, 2004. Severity of heart failure, treatments and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction. Eur. Heart J., 25: 1702-1710.
     CrossRef  |  Direct Link  |  
107. Karmpaliotis, D., M.P. Turakhia, A.J. Kirtane, S.A. Murphy and I. Kosmidou et al., 2004. Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am. J. Cardiol., 94: 1113-1117.
     CrossRef  |  Direct Link  |  
108. Giugliano, R.P., M.S. Sabatine, C.M. Gibson, M.T. Roe and R.A. Harrington et al., 2004. Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Am. J. Cardiol., 93: 1362-1367.
     PubMed  |  
109. Giugliano, R.P. and E. Braunwald, 2004. Baseline troponin in acute coronary syndromes managed invasively. Am. J. Med., 117: 963-965.
     CrossRef  |  Direct Link  |  
110. Giugliano, R.P. and E. Braunwald, 2004. ACC/AHA guideline for the management of patients with STEMI: The implications for clinicians. Nat. Clin. Prac. Cardiovasc. Med., 2: 114-145.
111. Gibson, C.M., S.A. Murphy, D.A. Morrow, J.M. Aroesty and R.J. Gibbons et al., 2004. Angiographic perfusion score: An angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. Am. Heart J., 148: 336-340.
     PubMed  |  
112. Gibson, C.M., S.A. Murphy, A.J. Kirtane, R.P. Giugliano and C.P. Cannon et al., 2004. Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol., 44: 980-987.
     PubMed  |  
113. Gibson, C.M., R.L. Dumaine, E.V. Gelfand, S.A. Murphy and D.A. Morrow et al., 2004. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome: Observations in 13, 307 patients in five TIMI trials. Eur. Heart J., 25: 1998-2005.
114. Gibson, C.M., L.K. Jennings, S.A. Murphy, D.P. Lorenz, R.P. Giugliano et al., 2004. Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: An INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. Circulation, 110: 679-684.
     PubMed  |  
115. Gibson, C.M., J. Karha, S.A. Murphy, J.A. de Lemos and D.A. Morrow et al., 2004. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. J. Am. Coll. Cardiol., 43: 1170-1176.
     PubMed  |  
116. Gibson, C.M., J. Karha, R.P. Giugliano, M.T. Roe and S.A. Murphy et al., 2004. Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. Am. Heart J., 147: 847-852.
117. Gibson, C.M., B. Bigelow, D. James, M.R. Tepper and S.A. Murphy et al., 2004. Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. Am. J. Cardiol., 94: 108-111.
     Direct Link  |  
118. Gardner, G.S., D.R. Frisch, S.A. Murphy, A.J. Kirtane and R.P. Giugliano et al., 2004. Effect of rescue or adjunctive percutaneous coronary intervention of the culprit artery after fibrinolytic dministration on epicardial flow in nonculprit arteries. Am. J. Cardiol., 94: 178-181.
     PubMed  |  
119. Allen, L.A., C.J. O'Donnell, R.P. Giugliano, C.A. Camargo and D.M. Lloyd-Jones, 2004. Care concordant with guidelines predicts decreased long-term mortality in patients with unstable angina pectoris and non-ST-elevation myocardial infarction. Am. J. Cardiol., 93: 1218-1222.
     PubMed  |  
120. Wong, G.C. and R.P. Giugliano, 2003. Low-molecular-weight heparins for the treatment of acute coronary syndromes. Semin. Vasc. Med., 3: 391-402.
     PubMed  |  
121. Lloyd-Jones, D.M., C.A. Camargo, L.A. Allen, R.P. Giugliano and C.J. O'Donnell, 2003. Predictors of long-term mortality after hospitalization for primary unstable angina pectoris and non-ST-elevation myocardial infarction. Am. J. Cardiol., 92: 1155-1159.
122. Ilkhanoff, L., C.J. O'Donnell, C.A. Camargo, D. O'Halloran, R.P. Giugliano and D.M. Lloyd-Jones, 2003. The TIMI Risk index predicts in-hospital and long-term mortality in unselected patients with myocardial infarction. Acad. Emerg. Med., 10: 429-430.
     Direct Link  |  
123. Hobbach, H.P., C.M. Gibson, R.P. Giugliano, J. Hundertmark, C. Schaeffer, W. Tscherleniak and P. Schuster, 2003. The prognostic value of serum creatinine on admission in fibrinolytic-eligible patients with acute myocardial infarction. J. Thromb. Thrombolysis, 16: 167-174.
124. Giugliano, R.P., M.T. Roe, R.A. Harrington, C.M. Gibson and U. Zeymer et al., 2003. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. J. Am. Coll. Cardiol., 41: 1251-1260.
     PubMed  |  
125. Giugliano, R.P. and E. Braunwald, 2003. Selecting the best reperfusion strategy in ST-elevation myocardial infarction: Its all a matter of time. Circulation, 108: 2828-2830.
     CrossRef  |  Direct Link  |  
126. Giugliano, G.R., R.P. Giugliano, C.M. Gibson and R.E. Kuntz, 2003. Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am. J. Cardiol., 91: 1055-1059.
127. Gibson, C.M., W.J. Gibson, S.A. Murphy, S.J. Marble and C.H. McCabe et al., 2003. Association of the Fibonacci Cascade with the distribution of coronary artery lesions responsible for ST-segment elevation myocardial infarction. Am. J. Cardiol., 92: 595-597.
128. Gibson, C.M., J. Karha, S.A. Murphy, D. James and D.A. Morrow et al., 2003. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J. Am. Coll. Cardiol., 42: 7-16.
     PubMed  |  
129. Gibson, C.M., D.S. Pinto, S.A. Murphy, D.A. Morrow and H.P. Hobbach et al., 2003. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J. Am. Coll. Cardiol., 42: 1535-1543.
     CrossRef  |  Direct Link  |  
130. Gibson, C.M., A.J. Kirtane, S.A. Murphy, J. Karha, C.P. Cannon et al., 2003. Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. J. Thromb. Thrombolysis, 15: 189-196.
131. Christenson, R.H., E.V. Leino, R.P. Giugliano and R.D. Bahr, 2003. Usefulness of prodromal unstable angina pectoris in predicting better survival and smaller infarct size in acute myocardial infarction (The InTIME-II Prodromal Symptoms Substudy). Am. J. Cardiol., 92: 598-600.
132. Walsh, C.R., C.J. O'Donnell, C.A. Camargo Jr., R.P. Giugliano and D.M. Lloyd-Jones, 2002. Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction. Am. Heart J., 144: 1003-1011.
     CrossRef  |  PubMed  |  
133. Sabatine, M.S., C.H. McCabe, D.A. Morrow, R.P. Giugliano and J.A. de Lemos et al., 2002. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. Am. Heart J., 143: 966-970.
     PubMed  |  
134. Morrow, D.A., E.M. Antman, A. Sayah, K.C. Schuhwerk and R.P. Giugliano et al., 2002. Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial. J. Am. Coll. Cardiol., 40: 71-77.
     PubMed  |  
135. Antman, E.M., H.A. Cooper, C.M. Gibson, J.A. de Lemos and C.H. McCabe et al., 2002. Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II. Eur. Heart J., 23: 928-933.
     PubMed  |  
136. Schweiger, M.J., C.P. Cannon, S.A. Murphy, C.M. Gibson and J.R. Cook et al., 2001. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Am. J. Cardiol., 88: 831-836.
     PubMed  |  
137. Roe, M.T., R.P. Giugliano, R.A. Harrington, C.M. Gibson and J. Strony et al., 2001. Combination Reperfusion therapy for acute myocardial infarction with eptifibatide and tenecteplase: Design and methodology of the (INTEGRIlin and Tenecteplase for acute myocardial infarction). Integriti. Trial. Heart Drug, 1: 5-13.
138. Morrow, D.A., E.M. Antman, R.P. Giugliano, R. Cairns and A. Charlesworth et al., 2001. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: An InTIME II substudy. Lancet, 358: 1571-1575.
     PubMed  |  
139. Morrow, D.A., E.M. Antman, L. Parsons, J.A. de Lemos and C.P. Cannon et al., 2001. Application of the TIMI risk score for ST-elevation MI in the national registry of myocardial infarction 3. JAMA, 286: 1356-1359.
     PubMed  |  
140. Llevadot, J., R.P. Giugliano, E.M. Antman, R.G. Wilcox and E.P. Gurfinkel et al., 2001. Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction. Eur. Heart J., 22: 2104-2115.
     CrossRef  |  Direct Link  |  
141. Giugliano, R.P., J. Llevadot, R.G. Wilcox, E.P. Gurfinkel and C.H. McCabe et al., 2001. Geographic variation in patient and hospital characteristics, management and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II. Eur. Heart J., 22: 1702-1715.
     Direct Link  |  
142. Giugliano, R.P., C.V. Pollack Jr., G.X. Brogan Jr., M. Cohen and D.B. Diercks et al., 2001. Acute coronary syndromes: From the Emergency Department to the Catheterization Laboratory-integrating evidence from recent ACS/NSTEMI trials into clinical practice: An evidence-based review of recent clinical trial results and report on a roundtable discussion. J. Interv. Cardiol., 24: 119-136.
     CrossRef  |  PubMed  |  
143. Giugliano, R.P., C.H. McCabe, E.M. Antman, C.P. Cannon, F. van de Werf, R.G. Wilcox and E. Braunwald, 2001. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am. Heart J., 141: 742-750.
144. De Lemos, J.A., D.A. Morrow, C.M. Gibson, S.A. Murphy and N. Rifai et al., 2001. Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. Am. J. Cardiol., 88: 353-358.
     PubMed  |  
145. Walsh, C.R., D.M. Lloyd-Jones, C.A. Camargo, R.P. Giugliano and C.J. O'Donnell, 2000. Clinical trials of unfractionated heparin and low-molecular-weight heparin in addition to aspirin for the treatment of unstable angina pectoris: Do the results apply to all patients? Am. J. Cardiol., 86: 908-912.
     Direct Link  |  
146. Morrow, D.A., E.M. Antman, A. Charlesworth, R. Cairns and S.A. Murphy et al., 2000. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation, 102: 2031-2037.
     PubMed  |  
147. Lloyd-Jones, D.M., C.A. Camargo, R.P. Giugliano and C.J. O'Donnell, 2000. Effect of leukocytosis at initial examination on prognosis in patients with primary unstable angina. Am. Heart J., 139: 867-873.
     Direct Link  |  
148. Llevadot, J., R.P. Giugliano, C.H. McCabe, C.P. Cannon and E.M. Antman et al., 2000. Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials). Am. J. Cardiol., 85: 1409-1413.
     CrossRef  |  Direct Link  |  
149. Januzzi, J.L., S.S. Hahn, C.U. Chae, R.P. Giugliano and K. Lewandrowski et al., 2000. Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes. Am. J. Cardiol., 86: 713-717.
     Direct Link  |  
150. Giugliano, R.P., D.M. Lloyd-Jones, C.A. Camargo, Jr., M.A. Makary and C.J. O'Donnell, 2000. Association of unstable angina guideline care with improved survival. Arch. Int. Med., 160: 1775-1780.
     PubMed  |  
151. Giugliano, R.P., C.H. McCabe, R.F. Sequeira, M.J. Frey and T.D. Henry et al., 2000. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: Results of the TIMI 15A and 15B trials. Am. Heart J., 140: 81-93.
     CrossRef  |  Direct Link  |  
152. De Lemos, J.A., E.M. Antman, R.P. Giugliano, D.A. Morrow and C.H. McCabe et al., 2000. Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram. Am. Heart J., 140: 373-378.
153. De Lemos, J.A., E.M. Antman, R.P. Giugliano, D.A. Morrow and C.H. McCabe et al., 2000. Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. In TIME-II Investigators. Intravenous nPA for Treatment of Infarcting Myocardium Early-II. Am. J. Cardiol., 86: 1235-1237.
     PubMed  |  
154. De Lemos, J.A., E.M. Antman, R.P. Giugliano, C.H. McCabe and S.A. Murphy et al., 2000. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Am. J. Cardiol., 852: 299-304.
     CrossRef  |  Direct Link  |  
155. De Lemos, J.A., E.M. Antman, D.A. Morrow, J. Llevadot and R.P. Giugliano et al., 2000. Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy. Clin. Chim. Acta., 298: 85-97.
     PubMed  |  
156. De Lemos, J.A., E.M. Antman, C.M. Gibson, C.H. McCabe and R.P. Giugliano et al., 2000. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation, 101: 239-243.
     PubMed  |  
157. Coulter, S.A., C.P. Cannon, K.A. Ault, E.M. Antman and F. van de Werf et al., 2000. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: Results from TIMI (thrombolysis in myocardial infarction) 14. Circulation, 101: 2690-2695.
158. Antman, E.M., C.M. Gibson, J.A. de Lemos, R.P. Giugliano and C.H. McCabe et al., 2000. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur. Heart J., 21: 1944-1953.
     PubMed  |  
159. Lloyd-Jones, D.M., C.A. Camargo, R.P. Giugliano, C.R. Walsh and C.J. O'Donnell, 1999. Characteristics and prognosis of patients with suspected acute myocardial infarction and elevated MB relative index but normal total creatine kinase. Am. J. Cardiol., 84: 957-962.
     CrossRef  |  Direct Link  |  
160. Jang, I.K., D.F. Brown, R.P. Giugliano, H.V. Anderson and D. Losordo et al., 1999. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J. Am. Coll. Cardiol., 33: 1879-1885.
     CrossRef  |  Direct Link  |  
161. Gibson, C.M., S. Murphy, I.B. Menown, R.F. Sequeira and R. Greene et al., 1999. Determinants of coronary blood flow after thrombolytic administration. J. Am. Coll. Cardiol., 34: 1403-1412.
     CrossRef  |  Direct Link  |  
162. Gibson, C.M., K.A. Ryan, S.A. Murphy, R. Mesley and S.J. Marble et al., 1999. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. J. Am. Coll. Cardiol., 34: 974-982.
     CrossRef  |  Direct Link  |  
163. Gibson, C.M., K.A. Ryan, M. Kelley, M.J. Rizzo and R. Mesley et al., 1999. Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. Am. Heart J., 137: 1179-1184.
     CrossRef  |  Direct Link  |  
164. Antman, E.M., R.P. Giugliano, C.M. Gibson, C.H. McCabe and P. Coussement et al., 1999. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation, 99: 2720-2732.
     PubMed  |  
165. Lloyd-Jones, D.M., C.A. Camargo, P. Lapuerta, R.P. Giugliano and C.J. O'Donnell, 1998. Electrocardiographic and clinical predictors of acute myocardial infarction in patients with unstable angina pectoris. Am. J. Cardiol., 81: 1182-1186.
     CrossRef  |  
166. Lapuerta, P., G.J. L'Italien, S. Paul, R.C. Hendel and J.A. Leppo et al., 1998. Neural network assessment of perioperative cardiac risk in vascular surgery patients. Med. Dec. Making, 18: 70-75.
167. Giugliano, R.P., C.A. Camargo, D.M. Lloyd-Jones, J.D. Zagrodsky and J.D. Alexis et al., 1998. Elderly patients receive less aggressive medical and invasive management of unstable angina: Potential impact of practice guidelines. Arch. Intern. Med., 158: 1113-11120.
     PubMed  |  
168. Cannon, C.P., C.M. Gibson, C.H. McCabe, A.A. Adgey and M.J. Schweiger et al., 1998. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation, 98: 2805-2814.
     PubMed  |  
169. Boeve, T.J., G.L. Reed, N.C. de Oliveira, J. Titus and S. Janssens et al., 1998. Comparison of argatroban and hirudin for the reperfusion of thrombotic arterial occlusion by tissue plasminogen activator. J. Thromb. Thrombolysis, 6: 103-108.
     CrossRef  |  Direct Link  |  
170. Serebruany, V.L., I.K. Jang, R.P. Giugliano, T.J. Massey and R.P. Schwarz Jr., 1998. A Randomized, blinded study of two doses of novastan(R) (brand of argatroban) versus heparin as adjunctive therapy to recombinant tissue plasminogen activator (accelerated administration) in acute myocardial infarction: Rationale and design of the myocardial infarction using novastan(R) and T-PA (MINT) Study. J. Thromb. Thrombol., 5: 49-52.
     PubMed  |  
171. Giugliano, R.P. and J.J. Belbruno, 1987. Multiphoton-induced chemistry of thiirane. J. Photochem., 37: 263-271.
     CrossRef  |  
172. Michelsen, H., R.P. Giugliano and J.J. Belbruno, 1985. Photochemistry and photophysics of small heterocyclic molecules. J. Phys. Chem., Vol. 89. .
     Direct Link  |